BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 20, Issue 38
  • This Article
Peer-Review Report of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 14018-14032
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.14018
Table 2 Oncological outcome data n (%)
Ref.Median FU (mth)Pre-op CTPost-op CTExtent of cytoreduction/disease CCRS21-yr survival2-yr survival3-yr survival4-yr survival5-yr survivalMedian survival (mo)Local/distant recurrence
Portilla et al[33]36.2122% (regimen not stated)100% (regimen not stated)CC0-CC1 (14/18; 64)CC0-CC1 (91%)CC0-CC1 (64%)---Overall-
CC2-CC3 (4/18; 36)CC2-CC3 (43%)CC2-CC3 (14%)20
PCI < 12 (10/18; 56)PC1 < 12 (N/A)PCI < 12 (64%)
PCI > 12 (8/18; 44)PCI > 12 (N/A)PCI > 12 (14%)
Witkamp et al[34]38 (26-52)-72% (5-FU+ leucovorin)-82%45%23%---LR 28%
DR 17%
LR + DR 28%
Pilati et al[35]14.5 (6-34)0%-CC0-1 34/3468%31%---18LR 59%
DR 12%
LR + DR 18%
Verwaal et al[36]47.5 (1.3-88.3)-15% (leucovorin)R1 (54/106; 51)-----R1 11.1Unspecified recurrence 65%
R2a (37/106; 35)R2a 5.9
R2b (15/106; 14)R2b 3.7
Glehen et al[37]59.5-68% (5-FU + irinotecan leucovorin)CC0 (23/53; 43)CC0 85%CC0 54%--CC0 22%CC0 32.9Unspecified recurrence 19%
CC1 (11/53; 21)CC1 46%CC1 36%CC1 9%CC1 12.5
CC2 (19/53; 36)CC2 24%CC2 0%CC2 8.1
Mahteme et al[53]---CC0 (11/18; 61)-CRS + EPIC 60%--CRS + EPIC 28%CRS + EPIC overall 32; CC0 34.5 CC1-2 10-
CC1-2 (7/18; 39)Control arm 10%Control arm 5%Control arm: 14
Glehen et al[38]5354%40%CC0 (271/506; 54)CC0 87%-CC0 47%-CC0 31%MalesUnspecified recurrence 73%
CC1 (106/506; 21)CC1 79%CC1 29%CC1 15%16.8
CC2 (129/506; 25)CC2 38%CC2 6%CC2 0%Females
21.6
Shen et al[39]15 (3-85)75%-R0 (13/77; 17)--R0 69%-R0 55%R0 N/RUnspecified recurrence 68%
R1 (24/77; 31)R1 19%R1 19%R1 17.8
R2a (11/77; 14)R2a 28%R2a 14%R2a 12.7
R2b (9/77; 12)R2b 0%R2b 0%R2b 4.1
R2c (20/77; 26)R2c 6%R2c 0%R2c 5.0
Cavaliere et al[40]1672%-CC0 (102/120; 85)--Overall--19-
CC1 (9/120; 7)25.8%
CC2-3 (9/120; 7)CC0
33.5%
Kianmanesh et al[41]-70%75%--72%-44%38.4-
Gusani et al[42]35.9 (19-57.7)---78%37%37%--15.2-
Verwaal et al[26]96 (72-115)--R1 (22/54; 41)R1 95%R1 80%R1 58%R1 52%R1 45%CRS + HIPEC-
R2a (23/54; 43)R2a 65%R2a 20%R2a 10%R2a 10%R2a 10%22.2
R2b (9/54; 17)R2b 22%R2b 12%R2b 0%R2c 0%R2c 0%Systemic CT
12.6
Yan[17]14 (1-56)--CC0 (41/50; 82)CC0 85%-CC0 62%--CC0 37Unspecified recurrence 34%
CC1-3 (9/50; 8)CC1-3 51%CC1-3 0%CC1-3 14
Elias et al[54]95.7----CRS + HIPEC--CRS + HIPECCRS + HIPEC-
81%51%62.7
Systemic CTSystemic CTSystemic CT
65%13%23.9
Varban et al[43]14.6----HM 43.3%-HM 14.4%-HM 23-
No HM 36.8%No HM 17.4%No HM 15.8
Vaira et al[44]-55%-CC0 (29/40; 73)CC0 88%----Overall: 43-
CC2 (11/40; 27)CC2 42%CC0: 24
CC2: 9.7
Glehen et al[45]----81%58%39%34%28%--
Franko et al[55]-100--CRS + HIPECCRS + HIPECCRS + HIPECCRS + HIPECCRS + HIPECCRS + HIPEC-
90%65%50%42%25%34.7
Systemic CTSystemic CTSystemic CTSystemic CTSystemic CTSystemic CT
55%35%12%10%7%16.8
Quenet et al[46]48.5100%-CC0 (132/146; 90)OverallOverallOverallOverall-OverallUnspecified recurrence 70%
CC1 (12/146; 8)92%72%55%50%41
CC2 (2/146; 2)
Cashin et al[56]HIPECHIPECHIPEC-HIPECHIPEC groupHIPEC groupHIPEC group-HIPEC group-
3881%38%100%78%60%48%36.5
EPICEPICEPICEPICEPIC groupEPIC groupEPIC groupEPIC group
6644%38%80%48%25%17%23.9
Passot et al[47]58.5 (1-183)75%64.30%CC0 (93/120; 78)OverallOverall--OverallOverall-
CC1 (11/120; 9)77%51%33%36.2
CC2 (16/120; 13)
Hompes et al[48]22.7 (3.2-55.7)-62.50%CC0 (48/48; 100)OS 98%OS 89%-----
DFS 66%DFS 46%
Cashin et al[57]49 (0.5-100)31%18%CC0 (97/151; 64)HIPECHIPECHIPECHIPEC-HIPEC-
CC1-3 (54/151; 36)80%50%27%18%34
EPICEPICEPICEPICEPIC
5%---25
Klaver et al[49]10.5 (1-52)--CC0 (22/24; 92)Overall----OverallUnspecified recurrence 54%
CC1 (2/24; 8)83%35
Turrini et al[50]----100%-51%-37%--
Haslinger et al[51]--------OS 38%--
PFS15%
Yonemura et al[52]-77%-CC0 (108/142; 76)----OverallOverall-
CC1 34/142 (24)23.4%24.4
CC0 20%CC0 25.9
CC1 9.9%CC1 8
1Peritoneal cancer index (PCI) - Calculated by combining lesion size (0-3; 0-no nodules present, 1-nodule(s) ≤ 5 mm diameter, 2-nodule(s) 5-50 mm in diameter, 3-nodule(s) ≥ 50 mm in diameter) with the abdominopelvic regions affected[33];
2Completeness of cytoreduction score (CCRS)[33]; CC0 No visible tumour remaining; CC1 residual tumour deposits < 2.5 mm in diameter; CC2 residual tumour deposits 2.5-25 mm in diameter; CC3 residual tumour deposits > 25 mm in diameter. HIPEC: Hyperthermic intraperitoneal chemotherapy; EPIC: Early post-operative intraperitoneal chemotherapy; CRS: Cytoreductive surgery; CT: Computed tomography.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.